
Acutaas Chemical Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
Yes
Order
N/A
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Revenue growth guidance for FY24 is revised to 15-18%, down from earlier 18-22% due to pricing erosion.
- For FY25, revenue growth is expected between 17-22%, driven by ramp-up in Fermion contract, new electrolyte products, and other projects.
- Volume growth has been strong at 25% year-on-year, indicating robust business traction despite pricing pressures.
- The company plans to achieve Rs. 1,000 crore revenue target by mid-FY26.
- Electrolyte additives supply has commenced commercially with long-term contracts signed; capacity expansion planned from 500 MT to 2,000 MT.
- New Ankleshwar plant inauguration and partnerships (e.g., with Fermion) expected to boost higher-value advanced intermediates production.
- Expansion in Specialty Chemical and Pharma Intermediate segments with product ramp-ups expected from Q1 FY25.
- Rs. 300 crore CAPEX underway (e.g., for electrolyte and Ankleshwar facility upgrades) to enable future growth.
See what Acutaas Chemical management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- Ami Organics has taken Rs. 119 crores of debt to fund the Ankleshwar facility capex.
- The total capex outlay for the Ankleshwar unit was revised upwards from Rs. 190 crores to Rs. 310 crores, involving additional machinery and infrastructure for a CDMO contract.
- The company plans to fund capex through a mix of internal accruals and debt; no mention of fresh equity fundraising was made.
- Finance cost for Q3 was Rs. 25 million and is expected to be similar or slightly higher next quarter due to additional capex borrowings.
- The overall debt-to-equity ratio after the recent debt is around 63% debt and 37% equity, indicating no immediate plans for equity dilution.
- No explicit future plans for new fundraising (debt or equity) beyond these were discussed in the call.
See what Acutaas Chemical management said on order book — free account, 30 seconds.
Capex plans
Yes- Total capex outlay for Ankleshwar unit revised from Rs. 190 crores to Rs. 310 crores due to additional machinery for CDMO contract and allied infrastructure.
- Rs. 119 crores debt taken to fund this capex, with overall funding through a mix of internal accruals and debt.
- Ankleshwar facility upgradation ongoing and expected to complete soon.
- Rs. 300 crores capex planned, mostly for electrolyte business, but deployment will take some time.
- Ankleshwar facility expected to have a turnover of 3-3.5x the asset value post-upgrade.
- No capital infusion planned currently for Baba Fine Chemicals acquisition; it is an established business.
- Capacity expansion planned for electrolyte additives: from current 500 metric tons each to an additional 2,000 metric tons each.
- Electrolyte CDMO business is CAPEX intensive with standard multi-year ramp-up timeline.
Track Acutaas Chemical — get its next earnings analysis in your feed
How does Acutaas Chemical rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Acutaas Chemical rank in Pharmaceuticals & Biotechnology?
Compare Acutaas Chemical against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Acutaas Chemical's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem